Pharmacognosy Journal, 2010; 2(5):38-43
Research Article | doi:Nill
In Vitro and In Vivo Anticoagulant Activity of Imperata Cylindrica a Novel Anticoagulant Lead from Natural Origin
Anticoagulant monotherapy has been the basis of treatment for patients with atrial fibrillation, left ventricular thrombus, as well as for prevention or treatment of deep venous thrombosis and pulmonary embolism. Considering the adverse effects with existing anticoagulant therapy, alternative drugs from natural origin can help to get the new molecular lead as a hope towards the better efficacious and safe anticoagulant. The present investigation was planned to evaluate the in vitro and in vivo anticoagulant activity of Imperata cylindrica (IC). Methanolic extract of IC has demonstrated presence of tannins and polyphenols. It can be concluded from the present investigation that IC has exhibited significant anticoagulant activity in vivo and in vitro. Oral administration of IC after 1, 2 and 3rd hr have exhibited 4, 6 and 9 fold increase in prothrombin time when compared to base value and 6, 7 and 9 fold increase in prothrombin time at 10th, 30 and 60th min after i.v. administration when compared to base value. IC may be acting on the extrinsic cascade of clotting probably by binding with the antithrombin. IC could be a hope towards development of a novel anticoagulant with optimized efficacy and reduced side effects.
Key words: anticoagulant, Imperata cylindrica, prothrombin time, ventricular thrombus.
Articles in PDF, ePUB and Full text are attached to this page. In order to download, print or access these formats you must be logged in.
Vancouver Style:AMA Style:CSE Style: